Conditions
Polyconditions.
One intelligence layer.
Each condition has its own clinical reality. AlfredAI treats them as one orchestrated panel — not nine point products.
HTN
Hypertension
BP control is a continuous problem — not an annual one.
- Prevalence
- 119 million US adults (CDC)
- Annual cost
- $131 billion / year
T2D
Type 2 Diabetes
Glycemic control between visits is where the disease is actually fought.
- Prevalence
- 38 million Americans
- Annual cost
- $413 billion total US economic cost
HF
Heart Failure
The warning signs of decompensation often appear days before an ED visit.
- Prevalence
- 6.7 million Americans
- Annual cost
- $30.7B today; projected $69.7B by 2030
AFib
Atrial Fibrillation
In AFib, consistent anticoagulation adherence is central to stroke prevention.
- Prevalence
- ~8 million; projected 12.1 million by 2030
- Annual cost
- $26B today; projected $45.4B by 2030
CKD
Chronic Kidney Disease
CKD is the silent multiplier behind every chronic-disease cost curve.
- Prevalence
- 35.5 million US adults (Stages 3–5)
- Annual cost
- $87.2 billion in Medicare spending alone
COPD
COPD
Visible adherence can help reduce COPD exacerbations.
- Prevalence
- 16 million Americans
- Annual cost
- $32 billion / year
CAD
Coronary Artery Disease
Secondary prevention is a daily discipline, not a discharge instruction.
- Prevalence
- 20.5 million US adults
- Annual cost
- Component of $239B total CVD direct costs
Obesity
Obesity
The GLP-1 era needs more than a prescription pad.
- Prevalence
- Over 100 million US adults (BMI ≥30)
- Annual cost
- $173 billion in medical costs
Lipids
Hyperlipidemia
Lipid targets only matter if patients stay on therapy.
- Prevalence
- ~86 million US adults with elevated LDL
- Annual cost
- Embedded within $239B CVD cost burden